Remebot / 睿米

About Remebot / 睿米

Beijing Remebot Technology Co., Ltd., operating as Remebot, is a medical device company focused on the development and production of surgical robots. The company was established in 2010 and is headquartered in Beijing, China. Remebot's founder and CEO, Liu Da, holds a Ph.D. from Beihang University and has been involved in medical robot research since 1998. His work, which began under Professor Wang Tianmiao, led to the creation of the first domestic neurosurgery robot prototype. This deep-rooted history in academic research, including winning a National Science and Technology Progress Award, formed the foundation for Remebot's commercialization journey.

Remebot develops, manufactures, and sells advanced surgical robot systems primarily for neurosurgery and, more recently, for dental implant procedures. The company's business model revolves around selling these high-tech systems to hospitals and healthcare organizations. Its client base includes numerous hospitals across China, where the robots are used to enhance surgical precision and efficiency. By providing tools that enable minimally invasive procedures, Remebot helps reduce patient trauma and recovery time while allowing surgeons to perform complex operations with greater accuracy.

The company's flagship product is the "Remebot" neurosurgical robot, the first of its kind to be certified by China's NMPA. This system assists surgeons by providing precise navigation and orientation during brain surgery. It integrates multi-modal imaging like CT and MRI to create 3D models of the brain, allowing for intelligent surgical planning. Key features include a robotic arm with a high degree of freedom, an optical tracking system for real-time navigation, and a positioning accuracy of less than 1mm. This technology is applied in procedures such as biopsies, hematoma drainage, and deep brain stimulation for conditions like Parkinson's disease. Remebot has also expanded its portfolio to include the "Ruibai®" dental implant robot, marking its entry into the oral surgery market. The company has successfully raised significant capital through multiple funding rounds, including a Series D round of 430 million yuan, to support market expansion and further product development.